TY - JOUR
T1 - Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer
T2 - Comparison of breast conservation and mastectomy
AU - Pierce, Lori J.
AU - Phillips, Kelly Anne
AU - Griffith, Kent A.
AU - Buys, Saundra
AU - Gaffney, David K.
AU - Moran, Meena S.
AU - Haffty, Bruce G.
AU - Ben-David, Merav
AU - Kaufman, Bella
AU - Garber, Judy E.
AU - Merajver, Sofia D.
AU - Balmaña, Judith
AU - Meirovitz, Amichay
AU - Domchek, Susan M.
N1 - Funding Information:
Acknowledgments This research was supported by the Breast Cancer Research Foundation (LJP, SDM); the Colebatch Clinical Research Fellowship of the Cancer Council Victoria (KAP), the National Health and Medical Research Council (NHMRC) of Australia (#145684, 288704, 454508) and grants from the National Breast Cancer Foundation, the NHMRC and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia (kConFab); Susan G. Komen Breast Cancer Foundation (BGH); Dana Farber/Harvard Cancer Center SPORE in Breast Cancer (JEG); and Cancer Genetics Network (HHSN21620074400C) (SMD). We thank follow-up study investigators, research nurses and staff at kConFab and all study sites, the heads and staff of the Australian and New Zealand Family Cancer Clinics, and the families who contribute to kConFab and to this international collaboration.
PY - 2010/6
Y1 - 2010/6
N2 - Women with BRCA1 and BRCA2 mutations have an elevated risk of breast cancer and ovarian cancer, but also of developing second primary breast cancer. BRCA1/2 mutation carriers with breast cancer must choose between breast conservation (BCT) and mastectomy (M) yet data on outcomes are limited. The purpose of this study is to compare long-term outcome following BCT and M in BRCAl/2 carriers. 655 women with BRCA1/2 mutations diagnosed with breast cancer and treated with BCT (n = 302) or M (n = 353) were identified and underwent follow-up to assess local, regional, and systemic recurrence. Local failure as first failure was significantly more likely in those treated with BCT compared to M, with a cumulative estimated risk of 23.5 vs. 5.5%, respectively, at 15 years (P < 0.0001); 15-year estimates in carriers treated with BCT and chemotherapy was 11.9% (P = 0.08 when compared to M). Most events appeared to be second primary cancers rather than failure to control the primary tumor. The risk of contralateral breast cancer was high in all groups, exceeding 40%, but was not statistically significantly different by use of adjuvant radiotherapy (RT) or not, suggesting no added risk from scatter RT at 10 and 15 years. There were no differences seen in regional or systemic recurrences between the BCT and M groups, and no difference in overall survival. In conclusion, BRCA1/2 mutation carriers with breast cancer have similar survival whether treated with M or BCT. However, women undergoing BCT have an elevated risk of a second in-breast event that is significantly reduced in the presence of chemotherapy. Contralateral breast cancer events are very common.
AB - Women with BRCA1 and BRCA2 mutations have an elevated risk of breast cancer and ovarian cancer, but also of developing second primary breast cancer. BRCA1/2 mutation carriers with breast cancer must choose between breast conservation (BCT) and mastectomy (M) yet data on outcomes are limited. The purpose of this study is to compare long-term outcome following BCT and M in BRCAl/2 carriers. 655 women with BRCA1/2 mutations diagnosed with breast cancer and treated with BCT (n = 302) or M (n = 353) were identified and underwent follow-up to assess local, regional, and systemic recurrence. Local failure as first failure was significantly more likely in those treated with BCT compared to M, with a cumulative estimated risk of 23.5 vs. 5.5%, respectively, at 15 years (P < 0.0001); 15-year estimates in carriers treated with BCT and chemotherapy was 11.9% (P = 0.08 when compared to M). Most events appeared to be second primary cancers rather than failure to control the primary tumor. The risk of contralateral breast cancer was high in all groups, exceeding 40%, but was not statistically significantly different by use of adjuvant radiotherapy (RT) or not, suggesting no added risk from scatter RT at 10 and 15 years. There were no differences seen in regional or systemic recurrences between the BCT and M groups, and no difference in overall survival. In conclusion, BRCA1/2 mutation carriers with breast cancer have similar survival whether treated with M or BCT. However, women undergoing BCT have an elevated risk of a second in-breast event that is significantly reduced in the presence of chemotherapy. Contralateral breast cancer events are very common.
KW - BRCA1/2
KW - Breast conservation
KW - Hereditary breast cancer
KW - Mastectomy
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=77953028921&partnerID=8YFLogxK
U2 - 10.1007/s10549-010-0894-z
DO - 10.1007/s10549-010-0894-z
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 20411323
AN - SCOPUS:77953028921
SN - 0167-6806
VL - 121
SP - 389
EP - 398
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -
